Featured
Featured posts

0 3148

There seems to be some confusion amongst the leaders of this incredible country.

In late February, White House press secretary Sean Spicer made an uneducated and informed connection between the opioid addiction crisis we currently face and recreational cannabis.

Spicer said, “There’s a big difference between that and recreational marijuana. I think that when you see the opioid addiction crisis blossoming in so many states around this country, the last thing we should be doing is encouraging people. There is still a federal law we need to abide by in terms of when it comes to recreational marijuana.”

Providing Real Facts…Not the Alternative Kind

In January, the National Academies of Sciences, Engineering and Medicine released a review of 10,000 medical cannabis studies published since 1999. The results strongly support the use of cannabis for the treatment of chronic pain.

In 2014, John Hopkins published a report that found the annual number of deaths from prescription drug overdose is 25% lower than in states where medical marijuana remains illegal.

Several reports actually link the opioid crisis we are currently facing to big pharmaceutical companies that liberally prescribed drugs like Oxycontin and Vicodin.

In late December, Department of Justice said several former employees of Insys Therapeutics (INSY), including its former CEO and president, had been arrested and charged with bribing doctors and defrauding health insurers to push prescriptions of Subsys, a fentanyl sublingual spray that has led to countless overdoses.

Biotech Stocks to Watch

The opioid crisis the United States faces combined with recent breakthroughs in research pertaining to the medical benefits of cannabis have created several attractive opportunities for biotech investors.

Some of the companies investors should be watching Future Farm Technologies Inc. (FFT.CN) (FFRMF), Vinergy (VIN.CN) (VNNYF), and InMed Pharmaceuticals Inc. (IN.CN) (IMLFF).

1 3396
cannabis biotech

One of the hottest sub-sectors of the cannabis industry was under pressure last week and investors have been able capture significant gains by buying the dips over the last six months.

Although cannabis cultivators and retailers have stolen the headlines for much of the last year, biotech companies focused on developing treatments from cannabis are going to be some of the biggest winners from the cannabis super cycle.

Biotech companies levered to the cannabis industry are some of the highest quality investment opportunities due to the exchange they trade on, access to institutional capital, strength of the management team, its longer term operating history, and its transparency and visibility.

The biotech companies that trade on the Nasdaq exchange are held to a higher level of accountability and transparency when compared to the biotech companies that trade on the over-the-counter exchange.

Betting on Biotech

Although the biotech industry offers a lot of opportunity, it presents even more risk. When we look at biotech investment opportunities, we look for companies that possess a competitive or unique advantage over their peers.

Some important factors we think are important to look at when considering a biotech investment include the following:

• Management: By far the most important (pedigree, track record, etc.)
• Balance Sheet Strength: Does it need money- clinical trials are not cheap
• Strategic Partnerships: Does it benefit from strategic relationships
• Product Pipeline: How advanced are they in the testing process.
• Illnesses Focused: Are they working on an illness with no current treatment
• Valuation: Does the current market cap offer limited or significant upside

Companies to Watch

Some of the cannabis stocks levered to the biotech sector that investors should have on their radar include: GW Pharmaceuticals (GWPH), Insys Therapeutics (INSY), Zynerba Pharmaceuticals (ZYNE),Vinergy (VIN.CN) (VNNYF), Emblem Corp (EMC.V) (EMMBF), and InMed $IMLFF $IN

0 1689

Vinergy Resources/MJ BioPharma Announces Memorandum of Understanding with Namaste Technologies Inc.

In the first phase of the collaboration, through channels in California, Colorado and potentially other States, the Company will distribute proprietary formulations to Namaste’s over 300,0000 unique visitors per month.

“We are excited and committed to working collaboratively with Namaste to bring to market our unique formulations. Namaste is an ideal partner based on their industry leading online presence and established customer base,” said Mr. Kent Deuters, CEO of MJ Biopharma.

“We are very pleased to work with Vinergy to further expand our product line. This relationship represents continued monetization of Namaste’s database and we view broadening our strategic alliances to the benefit of our customers and shareholders,” said Mr. Sean Dollinger, CEO of Namaste.

About Namaste Technologies Inc.

Namaste Technologies Inc. is an emerging leader in vaporizer and accessories space. Namaste has 26 ecommerce retail stores in 20 countries, offers the largest range of brand name vaporizers products on the market and is actively manufacturing and launching multiple unique proprietary products for retail and wholesale distribution. The Company is currently focused on expanding its product offering, acquisitions and strategic partnerships, and entering new markets globally.

This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.

The CSE does not accept responsibility for the adequacy or accuracy of this release.

Vinergy Resources Ltd.

Glen Macdonald, Director

Cautionary Statement Regarding “Forward-Looking” Information

The forward-looking information contained in this press release is made as of the date of this press release and, except as required by applicable law, the Company does not undertake any obligation to update publicly or to revise any of the included forward-looking information, whether as a result of new information, future events or otherwise, except as may be required by law. By its very nature, such forward-looking information requires the Company to make assumptions that may not materialize or that may not be accurate. This forward-looking information is subject to known and unknown risks and uncertainties and other factors, which may cause actual results, levels of activity and achievements to differ materially from those expressed or implied by such information.

0 3188

As you may or may not know I love Biotech companies as investment opportunities! The reason being is the fact they trade unlike any other companies out there and there are tangible milestones they can hit which when positive send the market into a buying frenzy. In the last year I’ve written about GWPH, ZYNE and CARA which are all Big Board (Nasdaq) companies in Forbes quite successfully and ahead of the market. Today I am writing about INMED, a Canadian based biotech company with board members from Eli Lilly, MIT and a Chief Medical officer formerly of GW Pharmaceuticals who will be the focus of this interview.

InMed has already distinguish themselves as a leading Cannabinoid Pharmaceutical Company. As one of very first biotech companies that entered the Cannabinoid research space, they are uniquely positioned capitalize on the anticipated growth of the cannabis-derived pharmaceutical market by creating not just therapies, but efficient scientific procedures to create those drugs and more importantly patent new methods in the process that are bankable & universal for other companies.

Today I am pleased to bring to the subscribers of Marijuanastocks.com an exclusive interview InMed’s Chief Medical Officer; Dr. Ado Muhammed, MD, DPM, MFPM.

He knows a few things about with cannabinoid based drugs as he is the former Assoc. Medical Director for GW Pharmaceuticals. GW Pharma and was part of the development team that developed Sativex, a cannabinoid based drug for MS that has been approved in over 15 countries worldwide.

Dr. Muhammed is a proven leader in the development of cannabinoid therapies, having played a strategic role in the clinical development, R&D, and commercialization of these specialty drugs.

I asked him to explain what InMed is doing and what separates them from Pack.

Q: What initially attracted you to join InMed an earlier stage biotech company involved in cannabis based Pharmaceuticals…an area you have a unique perspective on?

A: Initially it was InMed’s approach to drug discovery using their Bioinformatic program. This precision in the discovery process was a far more advanced approach than I had seen before in my career. The ability to discover compounds intelligently and efficiently to treat disease creates a significant industry advantage for InMed. Also, their drug delivery approach- avoiding systemic exposure through topical/local delivery I believe has a therapeutic advantage over oral delivery in terms of safety and efficacy.

Q: What differentiates InMed from other leading cannabinoid Biotech companies that you have seen?

In addition to the bioinformatics I see two other areas where InMed has an industry advantage. Firstly, using plant equivalent compounds versus others developing synthetic compounds is a clear advantage in my opinion. This will improve the safety profile of InMed’s therapies while providing the efficacious results expected in the treatments. Secondly, the ability to produce cannabinoids in the biosynthesis process

On the other spectrum InMed’s natural compound approach using specifically identified cannabinoids is also unique. This approach vs others using whole plant extracts and oils, is a more efficient method in terms of clinical development. Efficiency in time and cost

A: I understand you were at UBC yesterday getting an update from the team on the biosynthesis program. What essentially is this program and why is it so important for InMed and its shareholders?

Q: Essentially biosynthesis is a process that can manufacture cannabinoids out of a biologic system. This is a well-known system, as evidenced in the manufacturing of insulin, which is used by millions of diabetics daily. Again, I will point to efficiency and precision. Manufacturing cannabinoids in a controlled laboratory environment and eliminating the significant costs and variables associated with the current methods. This will have a major impact on both drug quality & costs. Also, the ability to produce all of the 90+ cannabinoids at a uniform cost open up InMed’s therapeutic potential and will secure our position as a world leader in cannabinoid prescription drug development.

Q: Fast forward 3 years…what are your top 3 indications

A: Of course, Epidermolysis Bullosa our lead therapy. We would expect to be in Phase 3 trials within 3 years and moving quickly to registration. Glaucoma we are targeting to have advanced to a stage where it can be partnered within the next 12 months. I also predict our advancement of other indications within the dermatology/orphan drug space, including the treatment of acute and chronic pain using a topical approach.

4.) Final Thoughts on InMed for our subscribers?

a. InMed has created a tremendous amount of value in a short period as evidenced by the assets in this company. InMed has the opportunity to become a world leader in cannabinoid based medicines and we are well on our way. The team we have assembled has both experience and capabilities to execute on this ambitious goal.

CONCLUSION:

The Cannabis Biotech/Pharma Market Could Surpass $20 Billion by 2020, and while we see the MJ licensed growers offering “medical” marijuana” The big winners in the Cannabis financial space will clearly be the Biotech’s like GWPH, ZYNE, CARA and Vancouver Biotech IMLFF. If you are not familiar with how the US cannabis industry is being tilted towards pharma companies I suggest you read this.

InMed (IMLFF) is a company I have known for a while, actually since I got involved in this space. When I first heard about them and met them two years ago I thought to myself “I wonder how far along they will be in two years?” Well 2 years later and they are positioning themselves in MY OPINION for Buyout or Biotech Glory. They are the frontrunner for Cannabis based Biotech in Canada, but more importantly…….

INMED is completely insulated by Federal, Country or State Law as it relates to Cannabis because at the end of the day they are science based nerds that happen to be mapping the Genome of pot!

0 1669

Kimberly Cargile opened A Therapeutic Alternative Shop in 2009. She says her store serves more than 40,000 patients throughout California. In addition to buying marijuana products, patients can also take advantage of free services like massage therapy and yoga. Cargile stated, “I believe that a patient has a right to heal themselves by all means necessary. So we really are on the cutting edge.” There are 30 dispensaries in Sacramento that serve individuals with a doctor’s prescription for medical cannabis.

That number will soon increase as thousands of applications are expected for dispensaries that will sell cannabis to recreational users. A doctor’s prescription for cannabis is no longer necessary under the state’s Adult Use of Marijuana Act, but until 2018 there is no store where a person can legally buy marijuana without a prescription. The question is whether existing shops will open their businesses to recreational users next year. Cargile said, “We will stay medical. There are plenty of legit patients who come to us who really need our services. We believe that we’ll be able to stay sustainable in the face of quite a bit of competition from recreational stores.”

Nate Bradley, executive director of the California Cannabis Industry Association, says he’s spoken to dispensary owners who want to stay medical. But Bradley says many of them have changed their minds. He stated, “It’s just expanding your market. If you’re a business owner, why would you not want to expand your market?” Bradley says Prop 64 was written to complement California’s existing legal framework for medical cannabis. He says the goal is to have one system with two sets of retail licenses, one for medical cannabis and another for recreational marijuana. Bradley said, “But that is what we’d like to see for the long run instead of creating the bureaucracy of two separate systems with two separate sets of rules you have to be in compliance with.”

0 1244

Palmer Republican Shelley Hughes introduced a proposal recently (Senate Bill 6) that would Permit for the creation of an Alaska hemp industry fully separate from commercial cannabis. Hughes said she introduced the proposal after hearing from farmers in the Matanuska-Susitna Borough who would like to cultivate hemp, particularly to feed livestock. Hughes said, “I’m hoping it maybe, in a small way, opens up an economic opportunity for Alaskans.” She noted the vast array of goods that can be created from hemp (some estimate more than 25,000 possible products) including food and construction materials.

It is still unknown if the crop will be profitable in Alaska. Hughes pointed to a 1916 document from the Alaska Agricultural Experiment Stations that says hemp “fruited abundantly” during a summer crop in the then-territory. Former Senator Johnny Ellis introduced a similar proposal last session that did not make it through the Legislature. Hughes had to reintroduce it, and adjusted it after reviewing hemp federal guidelines. Under the proposal, hemp would be considered an agricultural product, and excluded from Alaska’s definition of cannabis. The hemp industry would be managed by the Division of Agriculture, instead of the Alcohol and Marijuana Control Office.

Strictly controlled, state-run hemp pilot programs were made legal at the federal level by the 2014 Federal Farm Bill. Under Senate Bill 6, Alaska’s farmers would be able to produce, process, and sell hemp. An individual, college, or the Alaska Department of Natural Resources could partake in the pilot program. Hemp would be defined in Alaska statutes as cannabis sativa L., containing no more than 0.3 percent THC. That’s the common definition both at a federal and state level, which the California-based Project CBD says originated from a 1976 taxonomic report by a Canadian plant scientist who never intended to create the legal standard for cannabis vs hemp.

0 2871

A new proposal before legislators in Salem is arranged to protect people who purchase cannabis in Oregon. It’s considered emergency legislation, which means that if passed, it would immediately take effect. This proposal comes after comments from the federal government about pushing back on the six states that have legalized cannabis. Back on February 24, 2017, White House press secretary Sean Spicer said, “I do believe you will see greater enforcement of it.”

When asked about medical cannabis, Spicer stated, “that is very different than recreational use, which is something the Department of Justice, I think, will be further looking into.” Currently, when you buy marijuana in Oregon, the business records your identification information to ensure you’re not purchasing more than the legal amount per day. The CEO of Cannabliss & Co. in Portland, Matt Price, says the need for minimal identification information is to ensure buyers are staying within the legal limit.

Price stated, “If I have to purge the system and come up with some crazy way to track individuals it would be easy for people to abuse those powers.” Senate Bill 863 does two things. First, cannabis dispensaries or retailers wouldn’t be able to keep anyone’s information for more than four days. Second, it would make it illegal for the retailer or dispensary to give anyone’s information to anyone else. On the bottom of the bill’s summary it states the emergency act is “necessary for the immediate preservation of the public peace, health and safety.”

Price stated, “There is a lot of fear in a new administration I think these guys are going to be a little more stringent but I don’t think they are going to be messing with any licensed legal state business.” Senator Floyd Prozanski is one of the key supporters of the bill he says the goal is to ensure voters got what they were expecting when they passed Measure 91. He says the hope would be to get the marijuana industry to be more like the alcohol industry, meaning marijuana stores check age but don’t keep consumers’ personal information.

0 1821

A report recently showed that legalized marijuana sales are already draining billions of dollars of profit from the black market each year. Each day more and more consumers choose to support their locally taxed and regulated retail outlet instead of an underground dealer. According to the Arcview Market Research report, Cannabis Market Research, Americans and their Canadian fellows spent $53.3 billion total on marijuana in 2016, but only $6.7 billion in the legal North American market. That means there is a lot of room for growth. CEO of Arcview, Troy Dayton stated, “The enormous amount of existing, if illicit, consumer spending sets cannabis apart from most other major consumer-market investment opportunities throughout history.”

Unlike other fast-growing markets, which include home video, mobile, and organic foods, “the cannabis industry doesn’t need to create demand for a new product or innovation, it just needs to move demand for an already widely-popular product into legal channels,” Dayton stated. He said that the sudden popularity of alternative ingestion methods also fueled growth in the legal market. He continued, “Consumers who would never smoke a joint are finding relief in other products, which offer a wide array of tastes, strengths, and experiences.”

With a well-established customer base and its voters giving the green light to bring cannabis out of the closet and over the counter via Prop. 64, California is sure to have a severe impact on the marijuana economy. Dayton stated, “The possibilities of innovation seem endless. Legalizing cannabis in the world’s sixth-largest economy will present great opportunities for cannabis industry participants. Entrepreneurs couldn’t ask for a better time to be part of an untapped market, but now is the time to make a plan if one is to be successful.”

0 2719

Vinergy Resources/MJ BioPharma Appoints Mr. Facundo Bacardi to Board of Directors

Mr. Bacardi is a member of the family that owns and controls Bacardi Ltd., a worldwide liquor manufacturer and distributor. From 1979 to 1991, he was the head of Bacardi’s manufacturing and distribution division for Nassau, Brazil, Trinidad and Central America. Since 1990, Mr. Bacardi has served as a Director of Suramericana de Inversiones, S.A., an investment company located in Panama. He is a founding shareholder of JSM Capital Holding Corp., a shareholder and Director of Global Arena Holdings, Inc. Mr. Bacardi is also on the Honorary Consul for the Bahamas in Panama.

“We are excited to have someone of Mr. Bacardi’s calibre and pedigree join our team. We look forward to working closely with him on our strategy to roll out products and technologies internationally,” said Mr. Kent Deuters, CEO of MJ Biopharma.

Mr. Bacardi, said: “I am happy to be joining the team at Vinergy and helping them move the business forward in the cannabis industry. Given my life-long experience in the spirits industry I see several areas in which I can add immediate value for the Company.”

Mr. Bacardi has been granted 100,000 options priced at $0.60, subject to CSE approval.

This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.

The CSE does not accept responsibility for the adequacy or accuracy of this release.

Vinergy Resources Ltd.

Glen Macdonald, Director

Cautionary Statement Regarding “Forward-Looking” Information

The forward-looking information contained in this press release is made as of the date of this press release and, except as required by applicable law, the Company does not undertake any obligation to update publicly or to revise any of the included forward-looking information, whether as a result of new information, future events or otherwise, except as may be required by law. By its very nature, such forward-looking information requires the Company to make assumptions that may not materialize or that may not be accurate. This forward-looking information is subject to known and unknown risks and uncertainties and other factors, which may cause actual results, levels of activity and achievements to differ materially from those expressed or implied by such information.

0 2749

Fort Myers, Florida Representative Ray Rodrigues recently revealed the first medical marijuana statutes. They would prohibit people from smoking cannabis or using edibles. Patients would also be banned from vaporizing marijuana if they are not terminally ill. Rodrigues’ proposal is even more restrictive than the laws that existed before Florida voted to legalize medical marijuana. Ben Pollara, United for Care’s campaign director stated, “It goes further than the current statute in terms of restricting medical marijuana. There was unanimous agreement that the new amendment would expand use.”

Rodrigues’ proposal defines the “medical use” of marijuana as “the acquisition, possession, use, delivery, transfer, or administration of marijuana authorized by a physician certification.” Specifically, however, the proposal says medical use does not include “possession, use, or administration of marijuana in a form for smoking or vaping, or in the form of commercially produced food items made with marijuana or marijuana oils, except for vapable forms possessed, used, or administered by or for a qualified patient diagnosed with a terminal condition.”

Rodrigues said, “The question we’ve been asking all day is, ‘Well, how can you ingest it?”. Before last year’s legalization vote, the state had already allowed low-tetrahydrocannabinol cannabis derivatives for terminally ill people under what was known as the “Compassionate Use” law. Under the old system, doctors could register on a state database and administer low-THC, high-cannabidiol medicines such as the “Charlotte’s Web” hemp extract.

Legislators included statutes mandating that a medical marijuana patient submit his or her state driver’s license and a second form of ID to obtain approved for medicinal cannabis. Patients can have their medical-marijuana licenses suspended if they are charged with any drug offense. The state can also revoke cannabis licenses once a patient is believed to be “cured.” People who want to administer drugs to individuals who can not take them themselves must undergo background checks and training courses. Both caregivers and patients will be issued photo ID cards. Patients will be prohibited from buying more than a 90-day supply of marijuana.

The proposal also sanctions an “education campaign” to publicize the “short-term and long-term health effects of marijuana use, the “legal requirements for licit use and possession of marijuana in this state,” and the “safe use of marijuana.” The proposal also sets up an impaired-driving education campaign. Pollara said, “I don’t know how malleable the bill is right now, but it can be amended. It’s a disappointing place to start, but I’d rather it be disappointing to start than disappointing to finish.”

Subscribe Now & Begin Receiving Marijuana Stocks News, Articles, Trade Alerts & MORE, all 100% FREE!

We are your #1 source for all things Marijuana Stocks, Subscribe Below!

Privacy Policy: We will NEVER share, sell, barter, etc. any of our subscribers information for any reason ever! By subscribing you agree we can send you via email our free e-newsletter on marijuana stocks related, articles, news and trade alerts. Further questions please contact privacy@marijuanastocks.com
Ad Placements